Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Refer to “Group Performance” and “Appendix-Alternative Performance Measures” in the financial report for the fourth quarter of 2024 for a reconciliation of underlying to reported results and ...

Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical ...

Following a pre-specified interim analysis, the Data Safety Monitoring Board (DSMB) recommended the DRAGON trial, a pivotal Phase 3 trial in ...

Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development ...

Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission - - Strengthened ...

Wesdome Gold Mines Ltd. (TSX:WDO, OTCQX:WDOFF) (“Wesdome” or the “Company”) today announced its results for the three and twelve months ended December 31, ...

Q4 2024 Earnings Call Transcript March 20, 2025 Amprius Technologies, Inc. beats earnings expectations. Reported EPS is $-0.1 ...

Independent mortgage banks (IMBs) and the mortgage divisions of chartered banks reported an average pre-tax net loss of $40 ...

2.42 PHP 0.02 0.83% ...

1 Day DITO -2.88% DJIA 0.92% S&P 500 1.08% Telecommunication Services -0.65% ...